Granted Patent B2

US 12,286,437 · App. 18/423,156 · Granted Apr 29, 2025

Inventors: Bradley P. Morgan (South San Francisco, CA); Chihyuan Chuang (South San Francisco, CA); Luke W. Ashcraft (South San Francisco, CA); Justin Ho (South San Francisco, CA); Alfredo Garcia (South San Francisco, CA); Aroop Chandra (Carmel, IN)

Assignee: CYTOKINETICS, INC.

C07D487/10A61P9/04

Abstract

Claims (25)

1. A method of treating a heart disease in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the heart disease is hypertrophic cardiomyopathy.

3. The method of claim 2 , wherein the hypertrophic cardiomyopathy is obstructive or nonobstructive or is caused by (i) sarcomeric mutations, (ii) non-sarcomeric mutations, or (iii) both sarcomeric mutations and non-sarcomeric mutations.

4. The method of claim 1 , wherein the heart disease is heart failure with preserved ejection fraction.

5. The method of claim 1 , wherein the heart disease is selected from the group consisting of diastolic dysfunction, primary or secondary restrictive cardiomyopathy, myocardial infarction and angina pectoris, left ventricular outflow tract obstruction, hypertensive heart disease, congenital heart disease, cardiac ischemia, coronary heart disease, diabetic heart disease, congestive heart failure, right heart failure, cardiorenal syndrome, and infiltrative cardiomyopathy.

6. The method of claim 1 , wherein the heart disease is or is related to one or more conditions selected from the group consisting of cardiac senescence, diastolic dysfunction due to aging, left ventricular hypertrophy, and concentric left ventricular remodeling.

7. A method of treating a disease or condition associated with hypertrophic cardiomyopathy in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the disease or condition is selected from the group consisting of Fabry's Disease, Danon Disease, mitochondrial cardiomyopathies, and Noonan Syndrome.

9. A method of treating a disease or condition that is associated with secondary left ventricular wall thickening in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the disease or condition is selected from the group consisting of hypertension, valvular heart diseases, aortic stenosis, Mitral valve regurgitation, metabolic syndromes, diabetes, obesity, end stage renal disease, scleroderma, sleep apnea, amyloidosis, Fabry's disease, Friedreich Ataxia, Danon disease, Noonan syndrome, and Pompe disease.

11. A method of treating a disease or condition that is associated with small left ventricular cavity and cavity obliteration, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

12. A method of treating heart failure with preserved ejection fraction in a subject in need thereof, comprising administering to the subject a compound of formula:

13. A method of inhibiting a cardiac sarcomere, comprising contacting the cardiac sarcomere with a compound of formula:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 3 , wherein the hypertrophic cardiomyopathy is caused by sarcomeric mutations.

15. The method of claim 14 , wherein the sarcomeric mutation is a mutation in myosin heavy chain β (MHC-β), cardiac muscle troponin T (cTnT), tropomyosin alpha-1 chain (TPM1), myosin-binding protein C cardiac-type (MYBPC3), cardiac troponin 1 (cTnI), myosin essential light chain (ELC), titin (TTN), myosin regulatory light chain 2 ventricular/cardiac muscle isoform (MLC-2), cardiac muscle alpha actin, or muscle LIM protein (MLP).

16. The method of claim 15 , wherein the sarcomeric mutation is a mutation in MHC-β.

17. The method of claim 15 , wherein the sarcomeric mutation is a mutation in cTnT.

18. The method of claim 15 , wherein the sarcomeric mutation is a mutation in MYBPC3.

19. The method of claim 3 , wherein the hypertrophic cardiomyopathy is caused by non-sarcomeric mutations.

20. The method of claim 19 , wherein the non-sarcomeric mutation is a mutation in protein kinase AMP-activated non-catalytic subunit gamma 2 (PRKAG2).

Assignments (2)

Continuity (3)

References Cited (152)